TAVIST
LOE ApproachingNDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST is an oral tablet antihistamine approved in 1977 for allergic conditions. As a small-molecule H1-receptor antagonist, it competitively blocks histamine effects to reduce allergy symptoms. The drug is indicated for allergy management and represents a legacy generation of first-generation antihistamines.
LOE Approaching
As LOE approaches, the brand team is likely in maintenance mode with minimal investment in growth initiatives or field expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAVIST offers minimal career growth opportunity as a legacy product in LOE. Roles are primarily defensive, focused on maintaining market share and managing generic transition rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on TAVIST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.